Recon: Pfizer tops expectations on strong demand for COVID products; FDA halts Sun Pharma’s dermatological drug trials
ReconMichael MezherBiologics/ biosimilars/ vaccinesDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy